ESMO ADVANCED COURSE PROGRAMME

PRECISION ONCOLOGY IN ONCOGENE-ADDICTED NSCLC: BRAF, KRAS, RARE EGFR, RET

Barcelona, Spain
1-2 September 2023

CO-CHAIRS
Sabina Berezowska, Switzerland
Jürgen Wolf, Germany

SPEAKERS
Keith Kerr, United Kingdom
Anna Kron, Germany
Sonja Loges, Germany
Fernando López-Ríos, Spain
Sanjay Popat, United Kingdom
Noemi Reguart, Spain
Albrecht Stenzinger, Germany

LEARNING OBJECTIVES

• To understand the biology of specific oncopgene-addicted NSCLC and the rationale for targeted treatment
• To review the targeted treatment strategies, including current approvals and ongoing trials, in patients with oncopgene-addicted NSCLC
• To learn about the best current practice regarding testing methodology and get an outlook on future developments
• To improve interdisciplinary collaboration between oncology and pathology by understanding individual challenges in testing and treatment
• To understand health-economical aspects of targeted treatment in NSCLC

ACCREDITATION

The programme of this event has been accredited with 8 ESMO-MORA category 1 points.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from

Lilly

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4, 6900 Lugano, Switzerland
Email: courses@esmo.org
www.esmo.org
Friday, 1 September 2023

09:00-09:10 Welcome and introduction
10’ Welcome and learning objectives introduction
Sabina Berezowska, CH and Jürgen Wolf, DE

09:10-10:55 Session 1 – Molecular target / Family of targets – BRAF
Chairs: Sabina Berezowska, CH and Sanjay Popat, UK

15’ Biology of the target / biomarker (function and roles in normal and tumour tissue homeostasis)
Keith Kerr, UK
5’ Q&A

20’ Update on the clinical efficacy of approved targeted agents: Formal indications, efficacy and toxicity
Noemi Reguart, ES
5’ Q&A

20’ Testing for the target / biomarker (assays, technicalities and practicalities, challenges for interpretation)
Keith Kerr, UK
10’ Q&A

20’ A clinicopathological case presented and discussed by a Molecular Tumour Board
Noemi Reguart, ES
10’ Q&A

10:55–11:25 Coffee break

11:25-13:10 Session 2 – Molecular target / Family of targets – KRAS
Chairs: Sonja Loges, DE and Fernando López-Ríos, ES

15’ Biology of the target / biomarker (function and roles in normal and tumour tissue homeostasis)
Sabina Berezowska, CH
5’ Q&A

20’ Update on the clinical efficacy of approved targeted agents: Formal indications, efficacy and toxicity
Sanjay Popat, UK
5’ Q&A

20’ Testing for the target / biomarker (assays, technicalities and practicalities, challenges for interpretation)
Albrecht Stenzinger, DE
10’ Q&A

20’ A clinicopathological case presented and discussed by a Molecular Tumour Board
Sanjay Popat, UK
10’ Q&A

13:10-14:10 Lunch

14:10-15:55 Session 3 – Molecular target / Family of targets – Rare EGFR
Chairs: Noemi Reguart, ES and Jürgen Wolf, DE

15’ Biology of the target / biomarker (function and roles in normal and tumour tissue homeostasis)
Fernando López-Ríos, ES
5’ Q&A
20’ Update on the clinical efficacy of approved targeted agents: Formal indications, efficacy and toxicity  
Sonja Loges, DE
5’ Q&A

20’ Testing for the target / biomarker (assays, technicalities and practicalities, challenges for interpretation)  
Albrecht Stenzinger, DE
10’ Q&A

20’ A clinicopathological case presented and discussed by a Molecular Tumour Board  
Sonja Loges, DE
10’ Q&A

20:00 Networking Dinner

Saturday, 2 September 2023

09:00-09:40 Session 4 – Precision oncology from the perspective of health economics  
Chairs: Keith Kerr, UK and Jürgen Wolf, DE
30’ Value / health economics of testing and targeting (incl. MCBS, ESCAT actionability, RWD)  
Anna Kron, DE
10’ Q&A

09:40-11:55 Session 5 – Molecular target / Family of targets – RET  
Chairs: Sabina Berezowska, CH and Sanjay Popat, UK
15’ Biology of the target / biomarker (function and roles in normal and tumour tissue homeostasis)  
Fernando López-Rios, ES
5’ Q&A

20’ Update on the clinical efficacy of approved targeted agents: Formal indications, efficacy and toxicity  
Jürgen Wolf, DE
5’ Q&A

10:25-10:55 Coffee break

20’ Testing for the target / biomarker (assays, technicalities and practicalities, challenges for interpretation)  
Fernando López-Rios, ES
10’ Q&A

20’ A clinicopathological case presented and discussed by a Molecular Tumour Board  
Jürgen Wolf, DE
10’ Q&A

11:55-12:05 Synthesis and wrap-up
Sabina Berezowska, CH and Jürgen Wolf, DE

12:05-13:05 Lunch